CA2471661A1 - Molecular hepatotoxicology modeling - Google Patents

Molecular hepatotoxicology modeling Download PDF

Info

Publication number
CA2471661A1
CA2471661A1 CA002471661A CA2471661A CA2471661A1 CA 2471661 A1 CA2471661 A1 CA 2471661A1 CA 002471661 A CA002471661 A CA 002471661A CA 2471661 A CA2471661 A CA 2471661A CA 2471661 A1 CA2471661 A1 CA 2471661A1
Authority
CA
Canada
Prior art keywords
genes
protein
expression
mrna
ests
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002471661A
Other languages
English (en)
French (fr)
Inventor
Donna Mendrick
Mark Porter
Kory Johnson
Brandon Higgs
Arthur Castle
Michael Elashoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocimum Biosolutions Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2471661A1 publication Critical patent/CA2471661A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA002471661A 2002-01-31 2003-01-31 Molecular hepatotoxicology modeling Abandoned CA2471661A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US6008702A 2002-01-31 2002-01-31
US10/060,087 2002-01-31
US36405502P 2002-03-15 2002-03-15
US36404502P 2002-03-15 2002-03-15
US60/364,045 2002-03-15
US60/364,055 2002-03-15
US43664302P 2002-12-30 2002-12-30
US60/436,643 2002-12-30
PCT/US2003/003194 WO2003064624A2 (en) 2002-01-31 2003-01-31 Molecular hepatotoxicology modeling

Publications (1)

Publication Number Publication Date
CA2471661A1 true CA2471661A1 (en) 2003-08-07

Family

ID=27670970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002471661A Abandoned CA2471661A1 (en) 2002-01-31 2003-01-31 Molecular hepatotoxicology modeling

Country Status (6)

Country Link
US (1) US20070027634A1 (https=)
EP (1) EP1476747A4 (https=)
JP (1) JP2005535285A (https=)
AU (1) AU2003214981A1 (https=)
CA (1) CA2471661A1 (https=)
WO (1) WO2003064624A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20050071088A1 (en) * 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
JP2007501617A (ja) * 2003-08-07 2007-02-01 ジーン ロジック インコーポレイテッド 初代ラット肝細胞毒性モデリング
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US8131473B1 (en) * 2004-05-20 2012-03-06 Metabolon, Inc. Data analysis methods for locating entities of interest within large, multivariable datasets
KR100565698B1 (ko) * 2004-12-29 2006-03-28 디지탈 지노믹스(주) 급성골수성백혈병(aml), b-세포형 급성임파구성백혈병(b-all), t 세포형 급성임파구성백혈병(t-all) 진단용 마커
JP5202296B2 (ja) * 2005-04-01 2013-06-05 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 肝臓傷害のバイオマーカー
US8048638B2 (en) * 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
US10957217B2 (en) 2006-08-25 2021-03-23 Ronald A. Weitzman Population-sample regression in the estimation of population proportions
US11151895B2 (en) * 2006-08-25 2021-10-19 Ronald Weitzman Population-sample regression in the estimation of population proportions
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
EP2264454A1 (en) * 2009-06-11 2010-12-22 Universiteit Maastricht Method for screening compounds for preventing the adverse effects of reactive oxygen species on eukaryotic cells
WO2012141674A2 (en) 2010-01-26 2012-10-18 Banyan Biomarkers, Inc. Compositions and methods relating to argininosuccinate synthetase
JP5804629B2 (ja) * 2011-07-29 2015-11-04 株式会社メディクローム 遺伝子発現変動解析による化学物質の毒性評価方法
EP3077823B1 (en) * 2013-12-05 2019-09-04 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
EP3389715A4 (en) 2015-12-14 2019-06-12 David K. Thomas COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION
JP2016104032A (ja) * 2016-02-23 2016-06-09 株式会社メディクローム 化学物質の生体毒性の評価方法
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2025192110A1 (ja) * 2024-03-11 2025-09-18 国立大学法人東北大学 ベクターおよびその使用、並びに医薬組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0680517T4 (da) * 1993-01-21 2005-05-02 Harvard College Fremgangsmåde og diagnostiske sæt til bestemmelse af en forbindelses toksicitet under anvendelse afstress-promotorer fra pattedyr
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US6228589B1 (en) * 1996-10-11 2001-05-08 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
CA2269669A1 (en) * 1996-11-04 1998-05-14 3-Dimensional Pharmaceuticals, Inc. System, method and computer program product for identifying chemical compounds having desired properties
US6165709A (en) * 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
WO1999010536A1 (en) * 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in granulocytic cells
CA2310621A1 (en) * 1997-11-20 1999-06-03 Smithkline Beecham Corporation Methods for identifying the toxic/pathologic effect of environmental stimuli on gene transcription
JP2002505852A (ja) * 1998-01-26 2002-02-26 シェーリング アクティエンゲゼルシャフト 化合物をスクリーニングするための遺伝子発現方法
US6403778B1 (en) * 1998-05-04 2002-06-11 Incyte Genomics, Inc. Toxicological response markers
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6132969A (en) * 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6203987B1 (en) * 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
EP1137809A1 (en) * 1998-12-09 2001-10-04 Vistagen, Inc. Toxicity typing using embryoid bodies
EP1147224A1 (en) * 1999-02-05 2001-10-24 WRAIR (Walter Reed Army Institute of Research) Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
US6372431B1 (en) * 1999-11-19 2002-04-16 Incyte Genomics, Inc. Mammalian toxicological response markers
US20010049139A1 (en) * 2000-03-23 2001-12-06 Eric Lagasse Hepatic regeneration from hematopoietic stem cells
KR100865664B1 (ko) * 2000-06-14 2008-10-29 비스타겐 인코포레이티드 간 줄기 세포를 사용하는 독성 타이핑
WO2002006537A2 (en) * 2000-07-13 2002-01-24 Curagen Corporation Methods of identifying renal protective factors
EP1364049A2 (en) * 2000-07-31 2003-11-26 Gene Logic, Inc. Molecular toxicology modeling
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
US7993907B2 (en) * 2001-05-08 2011-08-09 Mowycal Lending, Llc Biochips and method of screening using drug induced gene and protein expression profiling
EP1397144A4 (en) * 2001-05-15 2005-02-16 Psychogenics Inc SYSTEMS AND METHODS FOR MONITORING BEHAVIOR INFORMATION

Also Published As

Publication number Publication date
US20070027634A1 (en) 2007-02-01
JP2005535285A (ja) 2005-11-24
EP1476747A2 (en) 2004-11-17
WO2003064624A2 (en) 2003-08-07
EP1476747A4 (en) 2008-06-11
WO2003064624A3 (en) 2003-12-11
AU2003214981A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
CA2471661A1 (en) Molecular hepatotoxicology modeling
US7415358B2 (en) Molecular toxicology modeling
US20020119462A1 (en) Molecular toxicology modeling
US20070093969A1 (en) Molecular nephrotoxicology modeling
US20090197258A1 (en) Primary rat hepatocyte toxicity modeling
US7447594B2 (en) Molecular cardiotoxicology modeling
US20060063156A1 (en) Outcome prediction and risk classification in childhood leukemia
US20090220970A1 (en) Molecular toxicology modeling
US20090202995A1 (en) Molecular cardiotoxicology modeling
CA2471631A1 (en) Primary rat hepatocyte toxicity modeling
US20070055448A1 (en) Primary rat hepatocyte toxicity modeling
US20040014040A1 (en) Cardiotoxin molecular toxicology modeling
WO2005100989A2 (en) Hepatotoxicity molecular models
US20060240418A1 (en) Canine gene microarrays
WO2007022419A2 (en) Molecular toxicity models from isolated hepatocytes
US20100129790A1 (en) Method for Determining Phospholipidosis
Rosen Differential gene expression profile of human tonsil high endothelial cells: implications for lymphocyte trafficking
WO2006037025A2 (en) Molecular toxicity models from isolated hepatocytes
HK1160923A (en) Blood transcriptional signature of mycobacterium tuberculosis infection

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20100201